Oslo, 27 April 2017


  • Record first-quarter revenues of NOK 99.6 million (96.2 million)

  • All-organic growth of 3.6%

  • First quarter adjusted EBITDA of NOK 22.2 million (margin 22.3%)

  • Strong brands secured revenue growth and high market shares in all main categories

  • Product-line expansion through the launch of Paracetduo effervescent tablets and Nazamer Menthol nasal spray


Weifa ASA (OSE: WEIFA) had record first-quarter revenues in 2017 on higher sales within the categories: pain relief, cough & cold products and dermatology, which includes the Asan portfolio. Total revenues for the quarter was NOK 99.6 million, representing an all-organic growth of 3.6% compared with the same period of 2016.


EBITDA was NOK 21.2 million (NOK 16.5 million) for the first quarter after NOK 1.0 million (NOK 5.5 million) in cost of employee options and other costs. The EBITDA margin adjusted for these costs was 22.3% (22.8%). Weifa’s portfolio of long-established brands maintained a high market share in all key segments during the quarter.


“We maintained a steady pace into 2017 with record first-quarter revenues. The launch of Nazamér Menthol and Paracetduo effervescent tablets extended our innovation track record, which together with rising demand for our main products are a key driver for our long-term growth,” says CEO Kathrine Gamborg Andreassen.


Weifa will give a presentation today at 08:30 CET at Felix Konferansesenter, Bryggetorget 3, Oslo, Norway. CEO Kathrine Gamborg Andreassen and CFO Simen Nyberg-Hansen will represent the company. The presentation will also be webcast live and can be accessed directly from:



Questions may be submitted live during the presentation.


Please find the report and presentation for the first quarter enclosed. The report and presentation will also be made available on www.weifa.no/investor.


For further information, please contact:


Kathrine Gamborg Andreassen


+47 9517 8680



Simen Nyberg-Hansen


+47 9820 6355



Presentasjon Q1

Rapport Q1